What is the appropriate diagnostic and therapeutic approach for a 54-year-old obese female (BMI ≈ 44) presenting with one-month progressive exertional dyspnea, one-year low back pain, positive HLA‑B27, currently on sulfasalazine 500 mg twice daily, tachycardia, normal SpO₂, and borderline diastolic hypertension?

Approach to a 54-Year-Old Female with Exertional Dyspnea, Chronic Low Back Pain, HLA-B27 Positivity, and Severe Obesity

This patient requires urgent evaluation for three distinct but potentially overlapping conditions: axial spondyloarthropathy (given HLA-B27 positivity and chronic back pain), cardiopulmonary causes of dyspnea (given severe obesity, tachycardia, and new exertional symptoms), and inadequate response to current sulfasalazine therapy.

Immediate Diagnostic Priorities

1. Evaluate the New-Onset Dyspnea (Most Urgent)

The one-month progressive exertional dyspnea with tachycardia (106 bpm) in a severely obese patient (BMI ~44) demands immediate cardiopulmonary assessment 1:

• Chest radiograph as the initial imaging study to identify obvious cardiac or pulmonary pathology
• CT chest without contrast if chest X-ray is abnormal or clinical suspicion remains high despite normal radiograph 1
• Echocardiogram to assess for:
  • Heart failure with preserved ejection fraction (HFpEF), which is highly prevalent in obesity 2, 3
  • Structural/functional cardiac abnormalities
  • Pulmonary hypertension
• BNP or NT-proBNP levels: Critical caveat—use lower thresholds in obese patients as obesity reduces natriuretic peptide concentrations, risking underdiagnosis of heart failure 2, 3
• Cardiopulmonary exercise testing (CPET) if initial workup is non-diagnostic, as dyspnea in obesity can result from deconditioning, restrictive physiology, or increased oxygen cost of breathing without true cardiopulmonary disease 4, 5

Screen for obesity-related comorbidities that worsen dyspnea 2:

• Sleep-disordered breathing (ask about snoring, daytime sleepiness, witnessed apneas)
• Type 2 diabetes
• Atrial fibrillation

2. Reassess the Axial Spondyloarthropathy Diagnosis and Treatment

The one-year history of low back pain with HLA-B27 positivity strongly suggests axial spondyloarthropathy, but sulfasalazine 500 mg twice daily is inadequate therapy 6, 7:

Key diagnostic features to elicit 6:

• Is the back pain inflammatory? (improved with exercise, not relieved by rest, worse in latter part of night, morning stiffness >30 minutes)
• Duration >3 months
• Age of onset <45 years (she is 54, but onset was at 53)

Immediate actions:

• Order MRI of sacroiliac joints and spine (sagittal T1 and STIR sequences of cervicothoracic and thoracolumbar regions; coronal/oblique sacroiliac joints with T1 and STIR) 6. Plain radiography will miss early disease.

• Refer to rheumatology urgently 6

• Recognize that sulfasalazine is ineffective for axial disease 6, 7. The evidence shows sulfasalazine does not work for axial symptoms—it only benefits peripheral arthritis. At her current dose (500 mg BD = 1000 mg/day), she is receiving half the typical dose anyway 8.

Treatment escalation algorithm 6, 7:

1. NSAIDs are first-line for axial spondyloarthropathy and more effective than simple analgesia 6. However, use cautiously given her borderline diastolic hypertension (BP 110/90).

2. If inadequate response to ≥2 different NSAIDs at maximal doses over 1 month (or incomplete response over 2 months), escalate to TNF inhibitors 7. This is a strong recommendation based on 24 randomized controlled trials showing improvements in patient-reported outcomes and MRI inflammation.

3. Sulfasalazine and methotrexate are not effective for axial disease and should not delay TNF inhibitor initiation 6, 7.

3. Address Severe Obesity as a Disease Entity

With BMI ~44, obesity itself is a chronic disease requiring treatment 2:

Immediate assessments:

• Screen for obesity-related heart failure: "Obesity-related cardiomyopathy should be suspected in heart failure patients who weigh 75% or more than their ideal body weight, whose BMI is 40 kg/m² or greater" 9
• Check fasting glucose, HbA1c (diabetes screening)
• Blood pressure monitoring (she has borderline diastolic hypertension at 90 mmHg)

Treatment considerations 2:

• If HFpEF is confirmed, consider GLP-1 receptor agonists (semaglutide or tirzepatide), which have shown improvements in symptoms, functional capacity, and potentially HF events in patients with BMI ≥30 and EF ≥45% 2
• Monitor closely during dose escalation: Check kidney function and electrolytes every 4 weeks, adjust diuretics and antihypertensives as needed 2
• Supervised exercise programs improve functional status in HFpEF 2

Integrated Diagnostic Algorithm

Step 1: Rule out life-threatening cardiopulmonary causes of dyspnea

• Chest X-ray → Echocardiogram → BNP (with obesity-adjusted interpretation) → CT chest if needed

Step 2: Confirm or refute axial spondyloarthropathy

• MRI sacroiliac joints and spine
• Rheumatology referral

Step 3: Optimize treatment based on findings

• If HFpEF confirmed: Guideline-directed medical therapy + consider GLP-1 agonist
• If axial SpA confirmed: Discontinue sulfasalazine → Trial NSAIDs → Escalate to TNF inhibitor if inadequate response
• Address obesity as primary disease with lifestyle intervention ± pharmacotherapy

Critical Pitfalls to Avoid

1. Do not attribute dyspnea solely to obesity or deconditioning without objective testing—this patient has new symptoms requiring evaluation 5, 3

2. Do not continue sulfasalazine for axial symptoms—it is ineffective and delays appropriate therapy 6, 7

3. Do not use standard BNP cutoffs—obesity lowers natriuretic peptides, requiring lower diagnostic thresholds 2, 3

4. Do not order plain X-rays of spine/SI joints—they miss early axial spondyloarthropathy; MRI is required 6

5. Do not assume tachycardia is benign—in the context of new dyspnea and severe obesity, it may indicate heart failure, pulmonary hypertension, or deconditioning requiring formal assessment 4, 10